logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Transient Ischemic Attack

    FiltersReset Filters
    5 results

    • aspirin and extended-release dipyridamole

      (Aspirin and Extended-Release Dipyridamole)
      AvKARE
      Usage: Aspirin and extended-release dipyridamole capsules are indicated for reducing the risk of stroke in patients with a history of transient ischemia of the brain or completed ischemic stroke due to thrombosis.

    • brilinta

      (Ticagrelor)
      AstraZeneca Pharmaceuticals LP
      Usage: BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also reduces the risk of first myocardial infarction or stroke in high-risk coronary artery disease patients and ischemic stroke/TIA patients.

    • ticagrelor

      (TICAGRELOR)
      Novadoz Pharmaceuticals LLC
      Usage: Ticagrelor is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It's also used in patients with coronary artery disease at high risk for first MI or stroke, and those with acute ischemic stroke or high-risk TIA.

    • ticagrelor

      (ticagrelor)
      Amneal Pharmaceuticals NY LLC
      Usage: Ticagrelor tablets are indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. They also prevent stent thrombosis and reduce the risk of first myocardial infarction or stroke in high-risk coronary artery disease patients.

    • ticagrelor

      (TICAGRELOR)
      AvKARE
      Usage: Ticagrelor tablets are indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also helps prevent first myocardial infarctions or strokes in high-risk patients with coronary artery disease and reduces stroke risk in acute ischemic stroke or high-risk TIA patients.